Literature DB >> 16023598

Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage.

Weikang Tao1, Victoria J South, Yun Zhang, Joseph P Davide, Linda Farrell, Nancy E Kohl, Laura Sepp-Lorenzino, Robert B Lobell.   

Abstract

The inhibition of KSP causes mitotic arrest by activating the spindle assembly checkpoint. While transient inhibition of KSP leads to reversible mitotic arrest, prolonged exposure to a KSP inhibitor induces apoptosis. Induction of apoptosis by the KSP inhibitor couples with mitotic slippage. Slippage-refractory cells show resistance to KSP inhibitor-mediated lethality, whereas promotion of slippage after mitotic arrest enhances apoptosis. However, attenuation of the spindle checkpoint confers resistance to KSP inhibitor-induced apoptosis. Furthermore, sustained KSP inhibition activates the proapoptotic protein, Bax, and both activation of the spindle checkpoint and subsequent mitotic slippage are required for Bax activation. These studies indicate that in response to KSP inhibition, activation of the spindle checkpoint followed by mitotic slippage initiates apoptosis by activating Bax.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023598     DOI: 10.1016/j.ccr.2005.06.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  88 in total

Review 1.  Targeted approaches for the management of metastatic prostate cancer.

Authors:  Kathleen W Beekman; Maha Hussain
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

Review 2.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

Review 3.  Spindle checkpoint function and cellular sensitivity to antimitotic drugs.

Authors:  Hiroshi Y Yamada; Gary J Gorbsky
Journal:  Mol Cancer Ther       Date:  2006-12       Impact factor: 6.261

4.  Dimeric Eg5 maintains processivity through alternating-site catalysis with rate-limiting ATP hydrolysis.

Authors:  Troy C Krzysiak; Susan P Gilbert
Journal:  J Biol Chem       Date:  2006-10-23       Impact factor: 5.157

5.  An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis.

Authors:  Weikang Tao; Victoria J South; Ronald E Diehl; Joseph P Davide; Laura Sepp-Lorenzino; Mark E Fraley; Kenneth L Arrington; Robert B Lobell
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

6.  Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis.

Authors:  Claire M Payne; Cheray Crowley-Skillicorn; Carol Bernstein; Hana Holubec; Harris Bernstein
Journal:  Clin Exp Gastroenterol       Date:  2011-05-03

7.  BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy.

Authors:  Dominik Schnerch; Andrea Schmidts; Marie Follo; Josefina Udi; Julia Felthaus; Dietmar Pfeifer; Monika Engelhardt; Ralph Wäsch
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

8.  Identification of the binding site of an allosteric ligand using STD-NMR, docking, and CORCEMA-ST calculations.

Authors:  Wei Zhang; Rongbao Li; Ronald Shin; Yimin Wang; Indira Padmalayam; Ling Zhai; N Rama Krishna
Journal:  ChemMedChem       Date:  2013-07-25       Impact factor: 3.466

9.  Identification of a mitotic death signature in cancer cell lines.

Authors:  Nandini Sakurikar; Joshua M Eichhorn; Sarah E Alford; Timothy C Chambers
Journal:  Cancer Lett       Date:  2013-10-04       Impact factor: 8.679

10.  Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells.

Authors:  Young Bin Hong; Hyo Jin Kang; Hee Jeong Kim; Eliot M Rosen; Sivanesan Dakshanamurthy; Riccardo Rondanin; Riccardo Baruchello; Giuseppina Grisolia; Simoni Daniele; Insoo Bae
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.